CorNeat Vision develops biomimetic implants and technology to address medical needs, including solutions for corneal blindness and other therapeutic fields. The company self-described harnesses the unique characteristics of microstructures of the human body for their synthetic implants.

CorNeat Vision

Viewport Meta

IPhone / Mobile Compatible

Euro

Apple Mobile Web Clips Icon

HSTS

Content Delivery Network

Google Cloud

PostalAddress Schema

COVID-19

PayPal

Head of Engineering

Ori Amsellem

Program and Project Management

Patricia Assouline

Operations

Lilach Zaks

VP Sales & Business Development

Gil Lotan

Accounting Bookkeeper

Lea Azaria

Marketing and Business Development Coordinator

Mai Akunis-Hermann

Vice President of Business Development

Almog Aley-Raz

Co-Founder, CEO, and VP R&D

Gilad Litvin

Co-Founder and Chief Medical Officer

Private Middle East Companies (Top 10K)

Israel Companies With Fewer Than 50 Employees (Top 10K)

Middle East and North Africa (MENA) Companies With Fewer Than 50 Employees (Top 10K)

Medical Device Companies (Top 10K)

CorNeat Vision is a clinical-stage, biomimetic implants and technology company. Our patented, nondegradable, synthetic, platform material - The CorNeat EverMatrix™ - is set to displace harvested and processed human and animal tissues, and degradable Extra Cellular Matrices (ECMs), the protein skeleton of the tissue, used in a variety of surgical procedures across diversified fields of medicine. 

The CorNeat EverMatrix™ addresses the main issue with implants and implantables – the foreign body response they trigger leading either to their degradation and absorbance, or encapsulation. The CorNeat EverMatrix™ seamlessly and permanently embeds with live tissue without triggering an inflammatory response. Its durability and flexibility, coupled with its bio-integration capabilities, mark a new era of implants that can:

•	Bio-mechanically integrate with surrounding tissue
•	Permanently reinforce soft tissue and accelerate its healing
•	Act as a membrane for guided soft tissue and bone regeneration
•	Conceal irritating implants
•	Enable sensors to continuously remain in contact with surrounding tissue

The features and benefits of the CorNeat EverMatrix™ were proven histologically and clinically in over a dozen in-vitro and in-vivo studies, including in humans.

Ra'anana

HaMerkaz

Israel

Asia

Israeli Startup CorNeat Vision Brings Eyesight to the Blind

CorNeat Vision raises $4 million from Israeli-Chinese GIBF fund

Sight returns to the blind with first-ever artificial cornea transplant

CorNeat Synthetic Cornea Implanted in First Patient

Israeli Startup CorNeat Has Brought Eyesight to the Blind – Literally

CorNeat Vision's First Patient Regains Sight Following Artificial Cornea Implantation at Rabin Medical Center, Ending a Decade of Blindness

Israeli medtech startup CorNeat Vision uses patented implants to treat blinding diseases

Israeli Startup’s Synthetic Cornea Approved for First Human Implantation

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation

A synthetic cornea designed to restore vision in patients with corneal blindness, pathology, and injury, integrating with ocular tissue using a skirt made from CorNeat EverMatrix™.

A non-degradable biomimetic material that mimics the human extracellular matrix, used for permanent attachment and integration of synthetic implants with live tissue.

A synthetic, non-degradable tissue substitute for ophthalmic surgeries, intended to reinforce the sclera and aid in ocular surface reconstruction.

A glaucoma drainage device designed to regulate intraocular pressure by draining excess aqueous humor into the intraconal space, minimizing the risk of scarring and tube exposure.

A permanent periodontal surgical matrix for guided bone regeneration and gingival recession surgeries, providing long-lasting mechanical support for gingival tissue regeneration.

India

Poland

Europe

United Kingdom

United States

North America

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 2:41 PM	d8e0ccd1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 2:41 PM	6879ac48
crunchbase trigger	general	Nov 25, 2024 9:06 AM	6284b377
crunchbase profile	general	Nov 25, 2024 10:36 AM	aa6b3c7e
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 4:21 PM	9c22048c
peers	general	Oct 16, 2024 2:41 PM	d667dbfb
news basic	general	Oct 16, 2024 2:41 PM	5ef308a0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CORNEAT

CorNeat Vision